Clinical Trial Update: A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation [Phase 1]

View source ↗

Summary

A Phase I study evaluating WT1 peptide immunotherapy to induce anti-leukemia immune responses after transplantation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• B-cell Malignancies
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• WT1 peptide vaccine (WT1 peptide vaccine)

Snippet

Sponsor: Michael Morse, MD | Conditions: Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML) | Phase 1 | Status: TERMINATED